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The metabolome of [2-14C]
(−)-epicatechin in humans: 
implications for the assessment of 
efficacy, safety, and mechanisms of 
action of polyphenolic bioactives
Javier I. Ottaviani1, Gina Borges2, Tony Y. Momma2, Jeremy P. E. Spencer3, Carl L. Keen2, 
Alan Crozier2 & Hagen Schroeter1
Diet is a major life style factor affecting human health, thus emphasizing the need for evidence-based 
dietary guidelines for primary disease prevention. While current recommendations promote intake 
of fruit and vegetables, we have limited understanding of plant-derived bioactive food constituents 
other than those representing the small number of essential nutrients and minerals. This limited 
understanding can be attributed to some extent to a lack of fundamental data describing the 
absorption, distribution, metabolism and excretion (ADME) of bioactive compounds. Consequently, 
we selected the flavanol (−)-epicatechin (EC) as an example of a widely studied bioactive food 
constituent and investigated the ADME of [2-14C](−)-epicatechin (300 μCi, 60 mg) in humans (n = 8). We 
demonstrated that 82 ± 5% of ingested EC was absorbed. We also established pharmacokinetic profiles 
and identified and quantified >20 different metabolites. The gut microbiome proved to be a key driver 
of EC metabolism. Furthermore, we noted striking species-dependent differences in the metabolism of 
EC, an insight with significant consequences for investigating the mechanisms of action underlying the 
beneficial effects of EC. These differences need to be considered when assessing the safety of EC intake 
in humans. We also identified a potential biomarker for the objective assessment of EC intake that could 
help to strengthen epidemiological investigations.
The crucial role of primary prevention in public health is undisputed. The role of diet and nutrition in the pro-
motion and maintenance of good health throughout all stages of life cannot be overestimated, and the need for 
the development of evidence-based dietary guidelines is well recognized. Current recommendations strongly 
promote the intake of fruits and vegetables1. However, although fruit and vegetables contain a vast number of 
bioactive constituents, our current understanding of their impact on human health is limited to a relatively small 
number of nutrients and minerals established to be essential for human life (e.g. vitamin C) and those very few 
non-essential nutrients, hereafter referred to as bioactives, for which a dietary guideline or daily reference intake 
has been established (e.g. dietary fiber)2. Consequently, there is an increasing need to comprehensively under-
stand the potential health benefits of bioactives. The demand for evidence-based insights and information about 
the health benefits of bioactives does not just come from the scientific community, but also from the public at 
large, as evidenced by the plethora of daily reports in the media on the putative benefits of a wide variety of foods 
ranging from green tea, blueberries, cocoa, and olive oil to red wine.
A critical assessment of the outcomes of current research in the wider area of bioactives and human health 
highlights significant gaps3 that can be attributed, to some extent, to a general lack of data describing the absorp-
tion, distribution, metabolism and excretion (ADME) of these compounds in humans. The availability and 
greater appreciation of ADME data will impact on all aspects of research in this area, including 1) the devel-
opment of objective biomarkers of intake, and thus the interpretation of epidemiological data on associations 
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between intake and health; 2) the assessment of safety and risks associated with intake; 3) the design and exe-
cution of dietary intervention studies and, perhaps most importantly, 4) the use of cell cultures in vitro and 
organ-/tissue preparations ex vivo that are aimed at elucidating the mechanisms of action that causally underlie 
observations in vivo. The latter point is of particular interest in relation to polyphenol and flavonoid research, as 
polyphenolic plant constituents such as (− )-epicatechin, (− )-epigallocatechin-3-O-gallate, quercetin, resveratrol 
and hesperetin comprise a large group of dietary compounds, many of which are currently being investigated in 
the context of health and nutrition3–5.
Regrettably, most of the hundreds of papers published in the context of investigating potential mechanisms of 
action of polyphenols using cell culture systems do not take into consideration the ADME of these compounds, 
generating data sets with limited utility. As almost all polyphenolic bioactives are subject to extensive metabolism 
in vivo, there is a clear need for testing their metabolites in ex vivo and in vitro model systems rather than the native 
compounds that occur in foods or plant extracts. Considering the above, and aiming ultimately at supporting an 
evidence-based approach to the development of dietary recommendations and applications, we studied the ADME 
in humans of a commonly consumed dietary flavonoid, namely the flavanol (− )-epicatechin (EC). The rationale for 
using EC as a representative example for bioactives, for which comprehensive data on ADME are needed, is as follows:
(1) Present in tea, pome fruit, cocoa, wine and various berries, EC is one of the most widely consumed flavanols, 
and it is absorbed and present in the systemic circulation of humans5,6.
(2) A considerable number of dietary intervention studies investigating the intake of flavanols such as EC have 
established their potential role in the primary and secondary prevention of cardiovascular disease and the 
secondary prevention of diabetes7–11.
(3) EC is one of the few nutrients for which a causal relationship between intake and the modulation of cardio-
vascular function has been established12,13.
(4) Methods for the de novo chemical synthesis of EC metabolites have been developed, allowing for the unam-
biguous synthesis of authentic standards for analytical method development and validation14–16.
(5) While widely investigated, the mechanisms of actions of EC are currently unknown, partly because only very 
few studies have investigated the biological effects of EC metabolites as systemically present in humans4.
(6) Validated biomarkers for human EC intake are urgently needed, but do not currently exist.
(7) Species equivalence of ADME, especially between humans and rodents, is currently assumed, but has not 
been validated, which represents a serious shortfall, as rodent models are frequently used in investigations 
aimed at assessing efficacy and safety.
While we and others have made significant advances in understanding the ADME of EC in humans6,17–20, 
the data obtained remain preliminary, exhibiting significant shortfalls and seeming contradictions6,12,18. In the 
absence of alternative approaches, such as the use of radiolabeled compounds, it is difficult to assess whether or 
not the reported disparities are merely due to technical limitations and inter-laboratory differences or actually 
reflect study-specific insights, such as differences in the ADME of EC as a function of the studied population 
(e.g. sex, age, dietary background, etc.) or the studied EC-containing foods and intake amounts (e.g. food matrix 
effects, nutrient-nutrient interactions, mastication- and digestibility-related differences in compound liberation). 
Furthermore, the role of the gut microbiome in the metabolism of EC in humans has only recently been recog-
nized19,21, increasing the complexity of the EC metabolome.
The current study was based on the oral intake by humans of radiolabeled EC, namely [2- 14C](− ) epicatechin 
(14C-EC; Fig. 1A), allowing for a comprehensive assessment of the ADME of this flavanol. We also focused on 
gaining novel insights into the role of the human gut microbiome in EC catabolism and, in addition, assessed the 
important question of species-dependent metabolic equivalence between humans and rodents. The outcomes 
of the study, which was conducted in the context of a standardized dietary background exposure to flavanols 
and their polymeric derivatives, the procyanidins, are intended to provide detailed insights into qualitative and 
quantitative aspects of EC ADME, which will help address current gaps and inconsistencies. Last, but not least, 
the data generated will be of value in support of efforts aimed at identifying EC-mediated mechanisms of action 
that underlie its protective effects.
Figure 1. (A) Chemical structure of [2-14C](− )-epicatechin. (B) Schematic representation of study design.
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Results
Study participants. Eight male volunteers were selected to participate in the 14C-EC ADME study. The 
basic biometric characteristics of the study group were: age, 31 ± 3 y; body weight, 75 ± 11 kg; body-mass index, 
24.5 ± 3.3 kg/m2; and systolic/diastolic blood pressure of 125 ± 11 over 74 ± 8 mm Hg. No adverse events related 
to the study treatment were recorded (Supplementary Table S1) and no significant clinical changes were noted 
from clinical laboratory evaluations, physical examinations and 12-lead electrocardiograms.
Oral administration of EC. Following the run-in phase (Fig. 1B), participants orally ingested 50 mL of a 
14C-EC-containing test drink, which delivered 60 mg (207 μ mol) of EC, and 300 μ Ci of radioactivity. Participants 
were discharged from the research facility 6 to 10 days (mean 8 ± 1 day) after the intake of the 14C-EC test drink, 
when radioactivity excreted in urine and feces over 24 h was < 1% of the amount administered.
Total radioactivity in circulation. Radioactivity was detected in the circulation 15 min after consumption 
(Fig. 2A). In whole blood, 2 radioactivity maxima were apparent at 1 h and at 6 h after 14C-EC consumption, with 
peak concentrations (Cmax) of 699 ± 65 nM and 516 ± 93 nM, respectively. Levels of radioactivity in whole blood fell 
below the limit of quantitation for all volunteers by 36 h post-consumption. Overall, the total amount of radioac-
tivity in the circulatory system at Cmax represented < 2% of the amount of 14C-EC ingested (Supplementary Fig. S1). 
Similar to the findings in whole blood, plasma also exhibited 2 radioactivity maxima at 1 h and at 6 h post-intake, 
with respective Cmax values of 1209 ± 104 nM and 952 ± 168 nM. Levels of radioactivity in plasma fell below the 
limit of quantitation for all volunteers by 72 h post-consumption. The total radioactivity present in whole blood 
was associated, almost exclusively, with plasma.
Elimination and mass balance. The elimination of 14C-EC-derived radioactivity was investigated in urine 
and feces (Fig. 2B). Accumulated radioactivity equivalent to 82 ± 5% of the amount ingested was eliminated in 
urine, with the majority being excreted within the first 24 h after intake. Accumulated radioactivity voided in feces 
accounted for 12 ± 3% of the ingested 14C-EC. Overall, radioactivity in urine and feces accounted for 95 ± 1% of 
intake, with 5 ± 1% that was not recovered in the collected samples.
Metabolite profiling. HPLC-MS2 coupled with an on-line radioactivity detector, identified and quanti-
fied > 20 14C-EC-derived metabolites in urine, which were classified in 1) structurally related EC metabolites 
(SREM), corresponding to O-glucuronidated, sulfated and O-methylated conjugates bearing an intact flavanol 
ring and represented mainly by (− )-epicatechin-3′ -O-β -D-glucuronide (E3′ G), (− )-epicatechin-3′ -sulfate (E3′ S), 
3′ -O-methyl-(− )-epicatechin-5-sulfate (3′ ME5S) and 3′ -O-methyl-(− )-epicatechin-7-sulfate (3′ ME7S); 2) 
5-carbon side chain ring fission metabolites (5C-RFM), corresponding to O-glucuronidated and sulfated deriva-
tives of 5-(3′ ,4′ -dihydroxyphenyl)-γ -valerolactone (γ VL), and 5-(3′ ,4′ -dihydroxyphenyl)-γ -hydroxyvaleric acid 
(γ OHVA), represented principally by 5-(4′ -hydroxyphenyl)-γ -valerolactone-3′ -sulfate (γ VL3′ S); and 3) 3- and 
1-carbon-side chain ring fission metabolites (3/1C-RFM), mainly in the form of 3-(3′ -hydroxyphenyl)hydracrylic 
acid, and the glycinated conjugates of benzoic acids, hippuric acid and 3′ -hydroxyhippuric acid (Table 1).
All of these EC-derived compounds were excreted in urine at different times. SREMs were the predominant 
urinary metabolites collected up to 4 h post-EC intake, whereas 5C-RFMs were the major compounds present 
from 4 to 12 h after intake. Finally, 3/1-C-RFMs became the main components in urine from 12 h onwards, until 
radioactivity fell below the limit of detection (Table 1).
Consistent with the findings from urine, the main SREMs in plasma were identified as E3′ G, E3′ S, 3′ ME5S 
and 3′ ME7S (Table 2, Fig. 3). The SREMs had a combined Cmax of 1223 ± 104 nM ~1.0 h after intake (Table 2). 
Figure 2. (A) Concentration in whole blood and plasma of [2-14C](− )-epicatechin -derived radioactivity 
as a function of time. Data expressed in nM as mean values ± SEM (n = 8). (B) Total [2-14C](− )-epicatechin 
-derived radioactivity in urine and feces as a function of time. Data are expressed in μ mol as mean values ± SEM 
(n = 8).
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[2-14C](−)-Epicatechin metabolites 
Urine collection periods
0–4 h 4–8 h 8–12 h 12–24 h 24–48 h 0–48 h
(− )-Epicatechin-3′ -O-glucuronide 8.0 ± 1.4 5.7 ± 1.3 2.9 ± 0.8 2.0 ± 0.8 – 18.6 ± 2.5
(− )-Epicatechin-3′ -sulfate 6.0 ± 0.7 1.2 ± 0.4 0.3 ± 0.1 0.2 ± 0.2 – 7.7 ± 0.9
(− )-Epicatechin-5-sulfate 1.3 ± 0.2 – – – – 1.3 ± 0.2
3′ -O-Methyl(− )-epicatechin-4′ -sulfate 0.7 ± 0.2 – – – – 0.7 ± 0.2
3′ -O-Methyl(− )-epicatechin-5-sulfate 7.1 ± 0.9 1.8 ± 0.3 0.4 ± 0.1 0.3 ± 0.2 – 9.6 ± 1.2
3′ -O-Methyl(− )-epicatechin-7-sulfate 0.9 ± 0.2 0.3 ± 0.1 – – – 1.2 ± 0.3
4′ -O-Methyl(− )-epicatechin-5-sulfate 1.0 ± 0.2 0.1 ± 0.1 – – – 1.1 ± 0.3
4′ -O-Methyl(− )-epicatechin-7-sulfate 0.3 ± 0.1 0.1 ± 0.1 – – – 0.4 ± 0.2
Sum of SREMs 25.3 ± 3.1 9.2 ± 0.9 3.6 ± 0.8 2.5 ± 0.8 – 40.6 ± 4.5 (20 ± 2%)
5-(Phenyl)-γ -valerolactone-sulfate-O-glucuronide-I 0.1 ± 0.1 0.9 ± 0.8 0.2 ± 0.2 0.4 ± 0.3 – 1.6 ± 0.7
5-(4′ -Hydroxyphenyl)-γ -valerolactone-3′ -sulfate 3.6 ± 1.1 16.0 ± 3.0 9.8 ± 2.0 8.1 ± 2.9 0.5 ± 0.5 38.0 ± 4.7
5-(Phenyl)-γ -valerolactone-3′ -sulfate 0.1 ± 0.1 2.4 ± 1.1 1.2 ± 0.9 1.0 ± 0.8 – 4.7 ± 2.7
5-(3′ -Hydroxyphenyl)-γ -hydroxyvaleric acid-4′ 
-sulfate; 5-(3′ -Hydroxyphenyl)-γ -valerolactone-4′ 
-O-glucuronide
0.2 ± 0.2 7.7 ± 1.5 3.7 ± 1.2 2.3 ± 1.2 – 13.9 ± 2.2
5-(4′ -Hydroxyphenyl)-γ -hydroxyvaleric acid-3′ 
-sulfate; 5-(4′ -Hydroxyphenyl)-γ -valerolactone-3′ 
-O-glucuronide; 5-(Phenyl)-γ -valerolactone-sulfate-
O-glucuronide-II
0.9 ± 0.6 13.1 ± 4.5 6.6 ± 1.3 3.4 ± 1.3 – 24.0 ± 5.2
5-(3′ -Hydroxyphenyl)-γ -hydroxyvaleric acid-4′ -O-
glucuronide – 1.3 ± 0.5 0.5 ± 0.3 0.5 ± 0.1 – 2.3 ± 0.7
5-(Phenyl)-4-hydroxyvaleric acid-3′ -sulfate – 1.9  ± 1.0 0.3 ± 0.2 0.7 ±  0.7 – 2.9  ± 1.6
Sum of 5C-RFMs 4.9 ± 1.6 43.3 ± 8.3 22.3 ± 4.1 16.4 ± 5.4 0.5 ± 0.5 87.4 ± 9.6 (42 ± 5%)
Hydroxyphenylacetic acid-sulfate – 0.9 ± 0.5 0.8 ± 0.6 1.2 ± 0.4 – 2.9 ± 1.1
3-(3′ -Hydroxyphenyl)hydracrylic acid – 0.7 ± 0.4 2.2 ± 0.5 5.3 ± 2.3 3.3 ± 1.7 11.5 ± 4.4
Hippuric acid 0.6 ± 0.4 7.2 ± 3.9 5.6 ± 2.6 7.1 ± 2.1 5.9 ± 4.1 26.4 ± 7.1
3′ -Hydroxyhippuric acid – 1.6 ± 0.5 2.8 ± 0.7 7.0 ± 2.9 5.5 ± 2.3 16.9 ± 5.8
Sum of 3/1C-RFMs 0.6 ± 0.4 10.4 ± 4.1 11.4 ± 2.5 20.6 ± 4.1 14.7 ± 5.5 57.7 ± 6.9 (28 ± 3%)
Table 1.  Human [2-14C](−)-epicatechin metabolites present in urine. Data are expressed as mean ± SEM in 
μ mol (n = 8); bold, italicized figures in parentheses represent urinary recoveries of metabolites as a percentage 
of (− )-epicatechin intake; SREMs–structurally related (− )-epicatechin metabolites; 5C-RFMs–5 carbon side 
chain ring fission metabolites; 3/1C-RFMs–3 to 1 carbon side chain ring fission metabolites;-not detected.
Subsequently, they declined rapidly and had all but disappeared from the circulatory system 8 h after 14C-EC 
ingestion (Fig. 3).
5C-RFMs were also detected in plasma but had different pharmacokinetic profiles than SREMs, having a delayed 
time to reach peak plasma concentration (Tmax) of ~6 h and longer elimination half-life (T1/2) values that ranged 
from 3.1–7.6 h (Table 2). The major 5C-RFM detected in plasma was γ VL3′ S, which was still present at a concentra-
tion of ~50 nM, 24 h after ingestion. Due to the low levels of radioactivity, 3/1C-RFMs were not assessed in plasma.
Species-dependent differences in the circulating profile of SREMs. Thirty min after intragas-
tric administration of 14C-EC to Sprague-Dawley rats (2 mg/kg BW; ~10.6 μ Ci/rat, n = 6), 2 major SREMs 
appeared in the circulatory system. They were 3′ -O-methyl(− )-epicatechin-5-O-β -D-glucuronide (3′ ME5G) and 
(− )-epicatechin-5-O-β -D-glucuronide (E5G) (Fig. 4). No unmetabolized EC and sulfated SREMs were detected.
C57BL/6 mice were also intragastrically administered with 14C-EC (2 mg/kg BW; ~6.7 μ Ci/mouse, n = 6) and, 
after 30 min, various SREMs, including E3′ S, E5G, 3′ ME5G, (− )-epicatechin-7-O-β -D-glucuronide (E7G) and 
3′ -O-methyl(− )-epicatechin-7-O-β -D-glucuronide (3′ ME7G), were detected in plasma (Fig. 4). No unmetabo-
lized EC was detected.
Discussion
Based on the use of the radiolabeled 14C-EC, we investigated the ADME of this flavanol in humans, under 
conditions relevant for interpretation of the outcomes in the context of dietary intake and nutrition. In 
summary:
1. EC is very well absorbed following oral intake in humans. The total 0–48 h recovery of radioactivity in 
urine accounts for 82 ± 5% of intake, whereas combined recovery in urine and feces represents 95 ± 1% of 
the ingested 14C-EC (Fig. 2B).
2. Extensive biotransformation gives rise to > 20 metabolites in plasma and urine (Tables 1 and 2, Fig. 3), with 
levels of unmetabolized EC below the limits of detection.
3. 20 ± 2% of the radioactivity detected in urine, which must have passed through the systemic circulation, 
was attributable to SREMs (Table 1).
www.nature.com/scientificreports/
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4. ≈ 70% of the ingested radioactivity was absorbed in the lower intestine, following catabolism by the gut 
microbiome that produced a series of RFMs, 42 ± 5% being metabolites of γ VL and γ OHVA and 28 ± 3% 
as derivatives of hippuric- and phenolic acids (Table 1).
5. Based on assessments of the SREMs in humans and two rodent species (Fig. 4), we cannot confirm species 
equivalence for EC metabolism.
6. Excepting effects exerted within the GI tract, the data presented here (Figs 3–5) make an unequivocal case 
for the need to test EC metabolites rather than native EC or EC-containing food extracts when aiming to 
investigate in vitro the molecular mechanisms that underlie EC bioactivities observed in vivo.
This study was conducted based on a defined exposure to dietary flavanols and procyanidins. The daily intakes 
by participants of EC, flavanol monomers, and procyanidins with a degree of polymerization (DP) of 2–10 prior to 
radiotracer administration were 40 mg, 45 mg, and 205 mg, respectively. In comparison, key dietary intervention 
studies using flavanol-containing foods provided an intake of EC ranging from 90–203 mg/day and procyanidins 
(DP 2–10) from 390–746 mg/day7–11. The habitual population-based intake of flavanol monomers (catechin/epi-
catechin) is reported as averaging 24 or 45 mg per day22,23, indicating that the EC intake investigated here (60 mg) 
is relevant and directly applicable in the context of habitual dietary intake and clinical dietary investigations.
The pharmacokinetic data for plasma presented in Table 2 and summarized in Fig. 5 indicate that the major 
SREMs are E3′ G, E3′ S, 3′ ME5S and 3′ ME7S (Figs 3 and 5). These metabolites exhibited Tmax values ranging from 
0.8 –1.4 h after ingestion of EC, indicative of absorption in the duodenum. SREMs were removed from the circu-
latory system via urinary excretion, with plasma T1/2 ranging between 1.1 and 2.0 h (Table 2). SREMs were absent 
from plasma after 6–8 h, but at this point the ingested EC had progressed down the GI tract and reached the colon. 
There, the microbiota induced opening of the C-ring, resulting in the formation of 5C-RFMs that, after phase II 
metabolism by enzymes arguably present in the wall of the colon and/or the liver, were represented by a mixture 
of sulfates and glucuronides of γ VLs and γ OHVAs that were detected in plasma and urine (Tables 1 and 2;Fig. 3). 
Most of these colon-derived metabolites remained in the circulatory system for an extended period of time 
(Table 2, Fig. 3). Overall, the results presented provide an accurate qualitative and quantitative description of the 
ADME of EC in humans.
Interestingly, analysis of radioactivity in whole blood and plasma (Fig. 2A) demonstrated that the pool of 
14C-EC metabolites is almost exclusively associated with plasma and not with cellular components of the blood. 
This finding answers a long-standing question regarding the interpretation of plasma level measurements in the 
context of assessing the total pool of circulating EC metabolites that may be present in cellular compartments of 
whole blood. Investigators have described the active transport and accumulation of γ VL into erythrocytes and 
have suggested that GLUT-1 facilitates this transport24. However, our data do not confirm the presence of 14C-γ VL 
in cellular components of whole blood, but instead identify significant levels of sulfated and glucuronidated γ VL 
[2-14C](− )-Epicatechin metabolites (number of isomers) Cmax (nM) Tmax (h) AUC0-24h (nM/h) T1/2 (h)
(− )-Epicatechin-3′ -O-glucuronide 359 ± 23 0.8 ± 0.1 1624 ± 332 2.0 ± 1.1
(− )-Epicatechin-7-O-glucuronide† 22 ± 7 0.8 ± 0.1 45 ± 14 1.7 ± 0.3
(− )-Epicatechin-3′ -sulfate 191 ± 17 1.1 ± 0.1 633 ± 135 2.0 ± 0.3
(− )-Epicatechin-5-sulfate 32 ± 4 0.8 ± 0.1 92 ± 25 1.9 ± 0.3
(− )-Epicatechin-7-sulfate† 19 ± 3 1.1 ± 0.2 43 ± 16 2.2 ± 0.4
3′ -O-Methyl-(− )-epicatechin-4′ -sulfate 53 ± 13 0.9 ± 0.1 203 ± 69 2.3 ± 0.6
3′ -O-Methyl-(− )-epicatechin-5-sulfate 240 ± 24 0.9 ± 0.1 915 ± 178 1.6 ± 0.1
3′ -O-Methyl-(− )-epicatechin-7-sulfate 159 ± 20 1.1 ± 0.1 1026 ± 260 2.4 ± 0.2
4′ -O-Methyl-(− )-epicatechin-5-sulfate 53 ± 14 0.9 ± 0.1 128 ± 45 1.4 ± 0.3
4′ -O-Methyl-(− )-epicatechin-7-sulfate 33 ± 5 1.4 ± 0.2 166 ± 54 2.6 ± 0.5
3′ -O-Methyl-(− )-epicatechin-5-O-glucuronide† 23 ± 5 0.8 ± 0.2 25 ± 10 1.3 ± 0.2
3′ -O-Methyl-(− )-epicatechin-7-O-glucuronide† 39 ± 5 0.9 ± 0.1 77 ± 31 1.3 ± 0.3
Sum of SREMs 1223 ± 104 1.0 ± 0.1 4943 ± 471 1.9 ± 0.1
5-(4′ -Hydroxyphenyl)-γ -valerolactone-3′ -sulfate 272 ± 56 6.4 ± 1.0 7595 ± 2684 6.3 ± 1.7
5-(3′ -Hydroxyphenyl)-γ -valerolactone-4′ -O-glucuronide 52 ± 9 6.1 ± 0.8 1329 ± 396 4.4 ± 1.3
5-(4′ -Hydroxyphenyl)-γ -valerolactone-3′ -O-glucuronide 125 ± 30 6.8 ± 0.8 1908 ± 787 3.1 ± 0.6
5-(Phenyl)-γ -valerolactone-O-sulfate-O-glucuronide (2) 39 ± 9 5.5 ± 1.1 1017 ± 481 6.4 ± 2.2
5-(Hydroxyphenyl)-γ -hydroxyvaleric acid-sulfate (2) 56 ± 9 5.9 ± 0.6 1492 ± 475 7.6 ± 3.5
5-(3′ -Hydroxyphenyl)-γ -hydroxyvaleric acid-4′ -O-glucuronide 54 ± 14 4.9 ± 1.3 835 ± 355 6.5 ± 0.8
Sum of 5C-RFMs 588 ± 102 5.8 ± 0.4 14352 ± 2264 5.7 ± 0.7
Table 2.  Pharmacokinetic parameters of human [2-14C](−)-epicatechin metabolites present in plasma. 
Data expressed as mean values ± SEM (n = 8). †metabolite detected in plasma but not in urine; Cmax–peak 
plasma concentration; Tmax–time to reach peak plasma concentration; AUC0–24h–area under the curve; T1/2–
elimination half-life; SREMs–structurally related (− )-epicatechin metabolites; 5C-RFMs–5 carbon side chain 
ring fission metabolites.
www.nature.com/scientificreports/
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metabolites in plasma, indicating that exposure of erythrocytes to native polyphenols or metabolic precursors ex 
vitro may lead to artifacts.
The timing of the appearance of the various radiolabeled compounds in urine over the 48-h period after inges-
tion of 14C-EC was in keeping with the plasma pharmacokinetic profiles that distinguished between components 
absorbed in the proximal GI tract and the colon. The accumulation of the metabolites in urine also provided 
quantitative information over and above that gleaned from plasma pharmacokinetic profiles (Tables 1 and 2). The 
total 0–48 h recovery of the individual radiolabeled metabolites in urine was 185.7 ± 16.3 μ moles of the ingested 
207 μ moles of 14C-EC (Table 1). This is a recovery of 90 ± 8% compared with an estimate of 82 ± 5% based on 
Figure 3. Concentration in plasma of [2-14C](−)-epicatechin metabolites as a function of time. SREM: 
structurally-related (− )-epicatechin metabolites. 5C-RFM: 5-carbon ring fission metabolites. Data are 
expressed as mean values in nM ± SEM (n = 8). Insert: pie charts depict the relative amount (% of total) of 
individual SREM and 5C-RFM present in plasma at 1 h, 4 h, 6 h and 12 h after 14C-EC ingestion (n = 8).
Figure 4. Species-dependent differences in [2-14C](−)-epicatechin metabolism. (A) Pie charts depict 
the relative amount (% of total) of individual SREM present plasma at 30 min post 14C-EC intake (mouse, 
rat) and at 1 h post 14C-EC intake (human). (B) Representative HPLC chromatograms of (yellow) SREM 
authentic standards (absorbance detection at 280 nm); (green) mouse-specific SREM (on-line radioactivity 
detection); (red) rat-specific SREM (on-line radioactivity detection); and (blue) human-specific SREM (on-line 
radioactivity detection).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:29034 | DOI: 10.1038/srep29034
liquid scintillation counting of the radioactivity in the unprocessed urine. These two estimates, which are not 
significantly different considering inter-individual differences, show that we can account for the great majority, 
if not all, of the EC metabolites that were systemically present in humans. In this context, we did not detect any 
oxidation products of EC, including ortho-quinones or any quinone-related adducts or derivatives of EC25,26. This 
finding represents a compelling argument against the common view that the systemic biological effects mediated 
by EC are predominantly based on direct antioxidant mechanisms involving hydrogen-/single electron transfer.
The urinary data summarized in Table 1 reveal that EC metabolites absorbed in the small intestine correspond 
to 20 ± 2% of intake, a figure that is in agreement with previous, albeit less precise, estimates of urinary excretion 
following ingestion of supplements containing a mixture of flavanols6. Most EC absorption occurred in the colon, 
with γ VL and γ OHVA metabolites being excreted in amounts corresponding to 42 ± 5% of intake. In addition, 
there was 28 ± 3% excretion of phenolic acids and hippuric acid metabolites (Table 1). Thus, in total, 70% of the 
ingested 14C-EC was absorbed into the circulatory system via the colon compared to 20% being absorbed from 
the small intestine. This finding highlights the importance of the colonic microbiome as a key factor for the 
absorption and metabolic fate of EC in the human body.
Our radiotracer-based data validate and significantly extend recent data on the identification of human 
EC metabolites obtained using standard 12C-EC-based approaches18. Also, recent findings by Actis-Goretta 
et al., which were not obtained using isotopically labeled compounds, can largely be confirmed in this con-
text20. However, Actis-Goretta et al., in a study of 5 individuals, reported the presence of (− )-epicatechin-4′ 
-β -D-glucuronide and (− )-epicatechin-4′ -sulfate that could not be identified by us, even though the use of a radi-
olabeled tracer should have enabled the detection of these compounds. While this discrepancy may be explained 
by inter-individual differences in EC metabolism, we have not observed such variations in EC metabolism in the 
present study, and it seems more likely that the compounds reported as EC metabolites by Actis-Goretta et al.20 
are in fact metabolites of the EC stereoisomer, (− )-catechin.
Variations in the published Tmax values for EC metabolites range from 0.8 h to 3.8 h6,18,20 and are most likely a 
consequence of differences in food matrix-specific effects, as the nature of the food matrix impacts mastication, 
gastric emptying, digestibility, etc., and therefore, the liberation of EC, and any other food constituent for that 
matter, from the ingested food. To exclude these potential confounders from this investigation, we chose to use a 
simple water matrix as the vehicle for EC ingestion. Nevertheless, questions related to the role of the food matrix 
in the ADME and Tmax of EC metabolites under real-life conditions remain pertinent from a nutritional perspec-
tive and should also be considered in the context of designing clinical dietary intervention studies.
While γ VLs generally have been identified previously as gut microbiome-derived flavanol metabolites in 
humans27,28, the data presented here provide a deeper understanding with regard to the identity as well as the 
pharmacokinetics of specific EC-derived γ VL metabolites present in humans. Considering factors such as 1) 
concentrations in urine and plasma; 2) T1/2; 3) specificity; 4) chemical stability; 5) temporality; and 6) consistency 
of observed occurrence29, γ VL metabolites represent far better candidates than SREMs for the development and 
Figure 5. Schematic representation of (−)-epicatechin metabolism in humans as a function of time 
post-oral intake. SREM: structurally related (− )-epicatechin metabolites. 5C-RFM: 5-carbon ring fission 
metabolites. 3/1C-RFM: 3- and 1-carbon-side chain ring fission metabolites. The structures of the most 
abundant (− )-epicatechin metabolites present in the systemic circulation and in urine are depicted.
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validation of objectives biomarkers for the dietary intake of EC and potentially, also procyanidins and other fla-
vanol monomers19. Future research may also be able to utilize stereochemistry-specific γ VL analyses to further 
increase the specificity of flavanol-/procyanidin-intake assessments.
The data depicted in Fig. 4 represent initial insights into the question of whether or not EC metabolism in 
humans is equivalent to that occurring in other mammals, in this case, rodents. While this question has relevance 
from a purely scientific perspective, as rodent models are frequently used to study the pharmacodynamic effects 
of drugs and nutrients in vivo, it also has regulatory relevance, especially with regard to the assessment of safety 
risks and potential toxicological effects in the context of drug and food ingredient safety. Although limited by 
the fairly small numbers of individuals investigated, and by assessing only the SREM-group of EC-derived com-
pounds, our data demonstrate considerable species-dependent differences in EC metabolism. Despite exhibiting 
similar metabolic themes, i.e., glucuronidation, sulfation, and methylation across species, the metabolism of EC, 
as judged by the profile of SREMs, is very different between humans and rats and, to a somewhat lesser degree, 
between humans and mice (Fig. 4). Of the 4 major SREMs present in humans, accounting for ≈ 80% of all SREM 
detected in humans, none was detected in rats, and only one of the SREMs detected in rats, namely 3′ ME5G, was 
present in humans, albeit in low abundance (< 3% of total SREM) (Fig. 4.). While more complex due to the higher 
number of SREMs detected, the situation in mice is similar, although perhaps less pronounced; of the 4 major 
SREMs present in humans, only two, E3′ S and 3′ ME5S, were detected in mice, representing ≈ 25% of all mouse 
SREMs identified (Fig. 4). Common principles of medicinal chemistry may predict that individual SREMs, while 
similar in chemical structure, would nevertheless have significantly different effects when interacting with any 
given target protein. However, in the absence of a confirmed mechanism of action or target protein, it is at present 
not possible to test this hypothesis. The data obtained here are preliminary to the extent that it is not possible to 
assess to what degree the ADME of EC varies as a function of the specific strain of rat or mouse and the intake 
level tested. Nevertheless, while further research is required, this finding should be carefully considered when 
evaluating the limitations, and thus the relevance, of rodent-based testing of the safety and efficacy of flavanols 
and indeed of other polyphenolic compounds for that matter. This is of particular relevance when considering 
recent reports regarding the safety of phytochemical-containing dietary supplements intake30.
Taken together, the data presented here provide detailed radiotracer-based insights into the ADME of EC in 
humans, which highlight the wider-ranging consequences of the interpretation of past and present data on the 
bioactivity of dietary flavanols in the context of epidemiological and clinical dietary intervention studies, as well 
as in vitro investigations based on cell culture systems. In addition, this investigation provides insights relevant for 
assessing the safety of EC and diets rich in flavanols, such as information for considering potential nutrient-drug 
interactions, as well as insights into potential limitations of rodent-based safety assessments. We hope that the 
outcomes of this investigation will also be of utility in guiding the design of future dietary intervention studies. It 
is also apparent that research using in vitro cell culture test systems should refrain from using flavanol-containing 
food extracts and unmetabolized EC and exercise caution when considering direct antioxidant mechanisms 
in the context of understanding the mode of action of flavanols in vivo. Considering this investigation from a 
broader perspective, it is evident that basic insights into the ADME of bioactives are of fundamental importance, 
and a greater appreciation and recognition of the practical relevance of ADME research in general would be of 
considerable benefit to many aspects of nutritional and biomedical research.
Methods
Chemicals. Authentic, de novo chemically synthesized EC metabolite standards (SI Materials and Methods), 
were synthesized and characterized as described elsewhere14–16 and supplied by the Institute of Pharmaceutical 
Discovery, LLC (Branford, CT). EC was provided by Mars Inc. (Hackettstown, NJ, USA). 14C-EC (Fig. 1A) was de 
novo synthesized by Quotient Bioresearch Ltd. (Cardiff, UK) according to Sharma et al.31 and tested and cleared 
for human use in this study. Other reagents were purchased from Fisher (Pittsburgh, PA).
Participants. We screened healthy, male volunteers between 18 and 50 years of age, with a body weight 
between 60 and 100 kg, and a body mass index between 19 and 30 kg/m2, as detailed in Supplementary Methods.
Human study design. The study was a single-center, open-label, and non-randomized study with two dis-
tinct elements: a run-in phase to establish a more defined dietary background of dietary flavanols and procy-
anidins and the subsequent 14C-EC ADME study (Fig. 1B). Participants (n = 12) were enrolled in the run-in 
phase (day –17 to day –4) and asked to supplement their daily diet for 14 days with a commercially available 
flavanol-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of EC). This was followed by a 4-day 
period (day –4 to 0) of a low-flavanol diet. One day (study day -1) prior to the initialization of the 14C-EC ADME 
study, all eligible participants were accommodated under controlled conditions at a metabolic research facility 
(Covance Clinical Pharmacology Inc., Wisconsin) until completion of the study. Based on the compliance of the 
first part of the study, 8 participants were selected to participate in the 14C-EC ADME study. During the 14C-EC 
ADME study (Fig. 1B.), volunteers received a low-flavanol, standardized high-fiber diet, and were encouraged 
to maintain an adequate level of hydration (water ad libitum). Volunteers were asked to fast for 8 h before the 
initiation of the study and for at least 4 h after the intake of the 14C-EC test drink (water ad libitum). Venous blood 
samples were taken using Vacutainer collection tubes, containing potassium EDTA at 0 h (just prior to 14C-EC 
ingestion), and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 h after test drink consumption. Plasma 
was obtained by whole blood centrifugation at 2000 × g for 15 min at 5 °C, separated into aliquots and stored 
at − 80 °C until analysis. All urine and feces from the time just prior to the consumption of the test drink were 
collected at different time intervals for radioactivity and metabolite profiling. Clinical parameters and laboratory 
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evaluations of participants were assessed at screening, on study day –1, and after completing the study, as detailed 
in Supplementary Methods.
Research ethics. The study protocol was approved by the Independent Institutional Review Board (Sunrise, 
Florida) in accordance with the United States Code of Federal Regulations governing Protection of Human 
Subjects (21 CFR 50), Financial Disclosure by Clinical Investigators (21 CFR 54), and IRB (21 CFR 56). In addi-
tion, this study was conducted under a Radioactive Drug Research Committee-approved protocol, in accordance 
with 21 CFR 361.1. All subjects gave their written informed consent to participate. This study was registered at 
clinicaltrials.gov (NCT01969994) in October 2013.
Run-in phase flavanol-containing drink. The drink consisted of a commercially available flavanol- and 
procyandin-containing, cocoa-based drink mix powder (CocoaVia, Mars Inc.) that was mixed with 240 mL of 
either water or milk (1% fat) and consumed once daily. Per serving, the drink provided 250 mg of cocoa flavanols, 
including 40 mg of EC and 205 mg of procyanidins (DP 2–10).
14C-EC test drink. The 50-mL drink consisted of an aqueous solution of 14C-EC (specific activity 14.5 μ Ci μ mol−1) 
and delivered 60 mg (207 μ mol) of EC and 300 μ Ci (660 × 106 dpm) of radioactivity. The drink was prepared one 
day before consumption to verify correctness of composition and stability. Volunteers received the 14C-EC test 
drink (50 mL), followed by 3 × 50 mL of water that was used to rinse the test drink container, and 40 mL of water. 
The radioactivity remaining in the test drink containers was measured, and the residual radioactivity recovered 
from each container was subtracted from the amount administered to the corresponding volunteer.
Measurement of total radioactivity. Radioactivity in aliquots of plasma and urine was measured by liq-
uid scintillation counting. Blood and feces were dried and oxidized by combustion using a 307 Sample Oxidizer 
(Packard Instrument Company, Meriden, NH) before being analyzed by liquid scintillation counting.
Metabolite profiling and quantification. Samples were processed as described previously18 and ana-
lyzed by HPLC-MS2 in conjunction with an on-line HPLC-radioactivity monitor as described in SI Materials 
and Methods. Identification of metabolites involved comparing the retention time with authentic standards and 
MS2 fragmentation patterns (Supplementary Methods). Quantification of metabolites in urine was based on 
HPLC radioactivity peak area (limit of quantification: 103 dpm). Due to the low levels of radioactivity, quanti-
fication in plasma was based on targeted HPLC-MS2 using standard curves obtained with authentic standards 
(Supplementary Methods).
Rodent study. All procedures involving rats and mice were approved by the Institutional Animal Care 
and Use Committees at Covance Laboratories (Madison, WI, USA) and the University of California Davis. 
Both institutions are accredited by AAALAC International (Association for Assessment and Accreditation of 
Laboratory Animal Care International). All procedures involving rats and mice were conducted in accordance 
with guidelines from the Animal Care and Use Committees at Covance Laboratories (Madison, WI, USA) and 
the University of California Davis conformed with the US Government Animal Welfare Act (7 U.S.C. § 2131) and 
the Health Research Extension Act (Public Law 99–158).
To assess the profile of SREMs in rodents, Sprague-Dawley rats (male, 9–10 week old, 270 ± 16 g of BW) and 
C57BL/6 mice (20 ± 1 g) were administered by gavage 2 mg/kg BW of 14C-EC (corresponding to ≈ 10.6 μ Ci/rat and 
6.7 μ Ci/mouse). Blood samples were collected 30 min after administration. Plasma was obtained by centrifugation 
at 4 °C for 15 min at 1800xg, separated in aliquots and analyzed by HPLC as described previously18 with an on-line 
radioactivity detector (Radiomatic 610TR Flow System Analyzer, PerkinElmer, Inc., Waltham, Mass).
Pharmacokinetic analysis. Data are expressed as mean values ± standard error, or as otherwise specified. 
Pharmacokinetic parameters were calculated using non-compartmental analysis with WinNonlin (Pharsight 
Corporation, Version 5.2).
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